Gemcitabine Ups Survival After Surgery in Pancreatic Cancer

English: Pancreatic Cancer Action logo
Gemcitabine Ups Survival After Surgery in Pancreatic Cancer


  • The main result of this trial is that treatment with adjuvant gemcitabine for 6 months leads to a 24% improvement in overall survival, with a statistically significant absolute 10.3% improvement in the 5-year overall survival rate (20.7% vs 10.4%) and a 4.5% improvement in the 10-year survival rate (12.2% vs 7.7%), compared with observation alone,
Enhanced by Zemanta

Populární příspěvky z tohoto blogu

Synoviální sarkom

Implatabilní port

Paraneoplázie